The clinical effectiveness of probiotics and autoprobiotics in treatment of Helicobacter pylori-associated dyspepsia

Cover Page

Cite item


The aim of our study was to evaluate the clinical performance of a monotherapy by Enterococcus faecium-based probiotics and indigenous autoprobiotics against H. pylori associated dyspepsia.

Materials and methods. There were examined 95 patients with dyspepsia. The entire patient cohort underwent clinical evaluation including filling out the questionnaire to assess dyspepsia symptoms before and after treatment, gastric endoscopy as well as gastric multi-focal biopsy (gastric body and gastric antrum) and verification of H. pylori infection with the three clinical laboratory methods (biochemical, bacteriological and molecular detection). An antagonistic in vitro activity of probiotics against H. pylori was detected by drop plate method for probiotic strains Enterococcus faecium SF68 and Bifidobacterium bifidum (Bifiform), Enterococcus faecium L3 (Laminolact), and autoprobiotic strains combined with indigenous Enterococcus faecium. To examine an antagonistic activity of probiotics and autoprobiotics in clinical trials, we used a starter culture based on the Enterococcus faecium L3 strain and an autoprobiotic based on indigenous Enterococcus faecium. The probiotic or autoprobiotic were administered orally to patients with gastritis twice a day at dose of 50 ml (8.0 lgCFU/ml) for 20 days. H. pylori eradication was assessed by stool antigen test 1.5–2 months after the end of treatment.

Results. Initially the H. pylori infection was confirmed with 49.4% of patients. The sensitivity of H. pylori to the probiotics was detected in 81% of individuals for indigenous Enterococci (the autoprobiotic), 76% — for Laminolact, and in 62% — for Bifiform. 22 patients with previous history of allergic reactions to antibiotics used in routine H. pylori eradication regimens were divided in two cohorts. One cohort (10 patients) received the autoprobiotic only, another cohort (12 patients) received only probiotic. Monotherapy with autoprobiotic resulted in 100% H. pylori eradication, single-agent therapy with probiotic led to 60% eradication of H. pylori. Dyspepsia symptoms were completely resolved in both groups of patients.

Conclusion. Our research demonstrated the sensitivity of examined H. pylori strains to be similar for traditional eradication treatment agents (antibiotics) and the proposed intervention agents (probiotics and autoprobiotics). An autoprobiotic monotherapy with indigenous enterococci led to higher levels of H. pylori eradication than with E. faecium L3-based probiotic agent. Our work demonstrated advantage for application of probiotics in patients with antibiotic allergies or other obstacles for the standard eradication therapy. Nonetheless, further investigation to better understand underlying mechanisms of action, as well as larger observational and randomized studies, are necessary to determine the scope of therapeutic application for probiotics and autoprobitics to eradicate H. pylori infection.

Full Text


Since the discovery of the role of Helicobacter pylori infection in the development of various diseases, particularly peptic ulcer and chronic gastritis, there has been a continuous search for improved methods of eradication of this microorganism. One potential way to improve anti-H. pylori treatment regimens is to include probiotics — medications (live microorganisms) that are used to improve the gut microbiota. An emerging need for new treatment agents for H. pylori eradication is growing in importance on the grounds of: 1) a decrease in the effectiveness of standard anti-H. pylori therapy due to an increase in H. pylori resistance to antibiotics, 2) side effects of proton pump inhibitors and antibacterial drugs, 3) reluctance of patients to take antibiotics [7]. Both international and Russian treatment guidelines allow for the use of probiotics. Both the fourth and fifth editions of the Maastricht Consensus Report state that some probiotics and prebiotics may be an effective supplement to standard eradication therapy [16, 17]. The clinical guidelines of the Russian Gastroenterological Association on the treatment of H. pylori infection in adults state that including probiotics in anti-H. pylori therapy improves therapy success and reduces the incidence of adverse events, namely remove the risk of C. difficile-associated diarrhea [2]. The VI Moscow Consensus of the Gastroenterological Scientific Society of Russia on the management of patients infected with H. pylori also emphasized that anti-H. pylori treatment is most effective and safe when supplemented with prebiotics or probiotics [3].

A number of meta-analyses demonstrated that the use of probiotics in addition to standard anti- H. pylori therapy improves both the effectiveness of eradication and reduces the frequency of side effects [15, 18, 20, 22, 24].

In addition, reduction of the side effects incidence of standard eradication therapy, some probiotics may have an antagonistic effect on H. pylori by inhibiting the growth of the microorganism. The undelying mechanism of descibed inhibition might be driven by producing antimicrobial products (bacteriocins, lactic acid, hydrogen peroxide and other) or by competing for survival (through colonization resistance) [6]. This prompted studies to evaluate the effectiveness of probiotic monotherapy in the treatment of H. pylori infection. This kind of therapy can be recommended for people who have allergic reactions to antibiotics, who are non-compliant to antibiotic therapies, as well as for family members of patients infected with H. pylori.

There are many of both Russian and foreign studies confirming the promising positive results of using probiotics monotherapy to eradicate H. pylori, with efficacy varying from 6 to 48% [6, 9, 10, 11, 13, 14, 19]. Probiotics are an emerging promising solution not only due to their ability to inhibit the growth of pathogenic microorganisms, but also because they are effective in restoring the composition of the gastrointestinal tract microbiota, as well as have a positive effect on the human immune system, mucus formation, and motility of the gastrointestinal tract [6].

However, the use of probiotics monotherapy, despite their high safety, also has its disadvantages: a relatively low eradication rate and a long course of treatment (1 month or more). The use of probiotic strains may not have a sufficiently significant antagonistic effect on H. pylori and a pronounced positive effect on the gastrointestinal microbiota, because they transit through the small intestine and colon. Moreover, it remains unclear how to choose a suitable probiotic for each individual.

Autoprobiotics, strains of normal microbiota isolated from a particular individual and designed to correct human microecology, are an innovative way to increase the effectiveness of eradication without producing negative effects on the microbiota. Autoprobiotics stay in the colon longer, which allows to reduce the time of treatment. Autoprobiotics prepared from native (indigenous) lactobacilli, bifidobacteria, or enterococci may become the drugs of choice, since immunological tolerance to them is formed from the first years of life, and they do not come into conflict with other the resident microbiota of the human body [21]. There already are studies showing the effectiveness of autoprobiotics based on indigenous strains of Lactobacillus spp. in the restoration and stabilization of the content of the main representatives of the normal gut microbiota (Bifidobacterium spp., Lactobacillus spp. and autoprobiotics based on E. coli) in treating dysbiotic disorders caused by the use of antibacterial drugs [1, 8], as well as indigenous strains of Enterococcus spp. in the treatment of intestinal pathology and neurological diseases [12].

The aim of our study was to evaluate the clinical performance of a monotherapy by probiotics and autoprobiotic Enterococcus faecium for H. pylori associated dyspepsia. We also evaluated gastric microbiota characteristics in the absence and in the presence of this microorganism.

Materials and methods

We examined 95 patients suffering from dyspepsia. Prior to commencing the study, all patients signed an informed consent to a comprehensive medical examination. The following groups were not included in the study: people who had received a course of eradication therapy within the previous two years, people who had taken antibiotics, proton pump inhibitors (PPIs), antacids, or bismuth containing drugs within the previous two weeks, as well as people with severe physical illnesses (including oncologic ailments) and/or infectious pathologies, pregnant and breastfeeding women.

The comprehensive examination prior to treatment included: survey to evaluate complaints (epigastric pain and signs of dyspepsia), gastroendoscopy, which included biopsies from gastric antrum and body to confirm H. pylori infection, and gastric microbiota analysis. The closing examination following the full treatment included an survey to evaluate complaints and collection of fecal samples to perform immunochromatographic stool tests for the detection of H. pylori.

Confirmation of Helicobacter pylori infection. Biochemical, bacteriological, immunological and genetic methods were used to confirm the presence of a pathogenic microorganism in the gastric mucosa. The result was considered positive when the infection was detected by all methods or by any one ofest the methods. The effectiveness of eradication was evaluated by determining the H. pylori antigen in feces.

Rapid urease test. We used the AMA RUT Expert test system to evaluate the urease activity of bacteria in the biopsy specimen and the AMA RUT Reader (AMA, Russia) for detection and record keeping. The AMA RUT Expert indicator is a test-slide with a well containing a reactive element sealed with a film. The slide has special marking on it, ensuring that the test results can be processed automatically.

Bacteriological method. Pure culture of the pathogen was isolated from biopsy specimens of gastric mucosa for each participant individually. Incubation protocol for H. pylori isolation microaerophilic conditions at 37°C for 5 days on the surface of a special culture medium (Columbia agar with 10% horse serum and 1% IsoVitalex, bioMerieux, France). The number of viable bacteria (CFU/g) was determined by plating corresponding 10-fold serial dilutions of biopsy specimens. Antimicrobial susceptibility testing performed with the disc-diffusion method, sensitivity to probiotics was determined by the drop plate method and the two-layer agar method. The bacteriological method is the gold standard in the diagnosis of helicobacteriosis, as it does not give false positive results, is specific and informative. Application of bacteriological method allowed our team to confirm that H. pylori was present in the sample, as well as to determine its sensitivity to antibiotics, probiotics, and autoprobiotics.

In addition to detecting H. pylori infection, we also performed a comparative analysis of gastric microbiota in the presence and in the absence of H. pylori. The viable bacteria count (CFU/g) in gastric biopsy specimens was determined by plating corresponding tenfold serial dilutions of suspensions on a number of selective dense culture media in Petri dishes and counting the bacterial colonies after incubation (24 hours) at 37°С. To determine the count of several genera of microorganisms such as E. coli, Enterococcus spp., Klebsiella spp., Proteus spp., Enterobacter spp. at the same time, we used the following chromogenic selective media: Pronadisa 1424 (Spain), HiCrome Coliform Agar (India). The lactobacilli count was determined by plating the culture on the Pronadisa 1043 Agar MRS medium (Spain) and culturing in anaerobic jars with gas generating sachets (Thermo Scientific AN0025A (USA)) at 37°C for 48 hours.

Polymerase chain reaction. PCR was used to detect the cagA and the vacA genes and thereby detect H. pylori in the biopsy specimens. This method was chosen because it is highly precise and informative. Moreover, features of the gastric microbiota were determined by molecular genetic study (real-time PCR) using the Colonoflor test system and 16S rRNA metagenomic analysis.

Quantitative polymerase chain reaction. Quantitative polymerase chain reaction (qPCR) was performed using the kit Colonoflor 16 (“AlphaLab”, Russia) corresponding to the set of marker colonic bacteria on the qPCR unit Mini-Opticon, BioRad. qPCR data on certain bacterial species were confirmed by classical bacteriology study.

Immune chromatographic test. The effect of probiotics and autoprobiotics used alone against H. pylori was evaluated by a non-invasive stool antigen test 1.5–2 months after treatment completion. Antigen determination in feces was carried out using the H&R H. pylori Vegal Farmaceutica S.L. test system, Spain.

Probiotic medication used for intervention. We used the probiotic autoprobiotic strains: Enterococcus faecium SF68 and Bifidobacterium bifidum (Bifiform, Ferrosan, Denmark) and (Enterococcus faecium L3 (Laminolact, “Avena”, Russia) to study antagonistic activity in vitro. Antagonistic activity was determined using the drop plate method. The investigated probiotics were diluted in distilled water at a ratio of 1:100 and then added to a dish with agar on which the H. pylori strain was plated. Growth was assessed on day 6–7.

We used a starter culture based on the Enterococcus faecium L3 strain to study the antagonistic activity in vivo. This strain was isolated from fermented milk, deposited in GenBank (No SUB167269, 2 629 318 base pairs, contains 2717 genes) and in the collection of the All-Russia Research Institute for Agricultural Microbiology, ND-79, patent in Russia No 2220199. Genes encoding the synthesis of several bacteriocins (including enterocins A, B, Enx α, and Enx β) were found in the genome of this strain. The probiotics were administered for 20 days. The probiotic was administered per os twice a day at doses of 50 ml (8.0 lgCFU/ml).

Autoprobiotics maiking. Autoprobiotics were obtained as described in Russian patent No. 2546253 [5]: at least 1 ml fecal samples were collected from patients who had not taken antibiotics and/or probiotics for at least 10 days prior to collection; clones of indigenous strains of Enterococcus faecium were isolated from the samples using a culture medium containing sodium azide and crystal violet dye; then, colonies were selected based on the coloring; pure cultures were obtained by plating three pink-colored colonies with a burgundy center onto three sectors of Petri dishes with the same medium and incubated in a thermostat under aerobic conditions at t = 37°C, and tested by PCR for absence of genes of pathogenicity; then, non-pathogenic clones were selected and cultured in a soy hydrolysate at no less than 10 ml per liter.

The 5% culture medium was prepared by diluting a lactose-free dry protein-vitamin mixture “Super LF” (SLF) in a small amount of distilled water heated to 40° C in a ratio of 1:1 until a homogeneous suspension was obtained. The resulting suspension was filtered through 4 layers of medical gauze and diluted with the remaining amount of distilled water (DW). The ratio of components by weight in the final suspension should be: DW:SLF = 95.5. The resulting suspension was dispensed into 1–2 L plastic bottles and autoclaved at 120° C and 1.2 atm for 15–30 minutes, then cooled to a temperature of 40°C.

Seed doses were prepared by aseptically taking 50 mg of lyophilized starter culture and inoculating it with 2 ml of 5% culture medium cooled to 40°C. They were then cultivated in an aerobical condition for 14–16 hours at 37°C. The grown cell culture was transferred into 300 ml of sterile 5% culture medium cooled to 40°C and incubated in a dry-air thermostat for 14–16 hours at 37°C. The resulting biomass was used as a seeding dose for 1–2 L of culture medium. The starter culture which changed the structure of hydrolysate earlier than others was selected and used to prepare two liters of individual autoprobiotic product containing at least 108 CFU per 1 ml, which was administered to the patient orally at a dose of 50 ml 2 times a day for at least 20 days.

Methods of statistical analysis of study results. Statistical processing of the results was carried out using Statistica 10 for Windows (StatSoft, USA). Nonparametric pairwise multiple-comparison was used to evaluate the effectiveness of diagnostic methods and treatments. A p-value < 0.05 was considered statistically significant.


Using various diagnostic methods, H. pylori infection was detected in 47 out of the 95 patients, or in 49.4% of the patients. The bacteriological method produced 21 positive results.

Evaluation of sensitivity of clinical isolates of Helicobacter pylori to antibiotics. We analyzed the sensitivity of the 21 isolated strains of H. pylori to the four antibacterial drugs most commonly used in the eradication therapy of H. pylori-associated diseases (Fig. 1).


Figure 1. Prevalence of detected of H. pylori strains sensitive to antibacterial drugs


The chart shows that the sensitivity to amoxicillin is the highest and reaches 100%, while sensitivity to metronidazole is half as high, with sensitivity to levofloxacin and clarithromycin falling between these two values. The data obtained are similar to the results of previous studies also conducted in St. Petersburg [4], which indicates a stable level of resistance of the pathogen to the antibacterial agents traditionally used in this region.

Evaluation of isolates of Helicobacter pylori isolates sensitivity to probiotics and autoprobiotics. The bacteriological (cultural) method also allowed to determine the sensitivity to probiotic and indigenous (autoprobiotic) strains of enterococci isolated from the fecal samples of patients prior to eradication therapy. According to the chart (Fig. 2), the highest number of clinical isolates were sensitive to indigenous enterococci (the autoprobiotic).


Figure 2. Prevalence of detected H. pylori strains sensitive to probiotics and autoprobiotics


H. pylori sensitivity to antibiotics and probiotics allows for personalized treatment of H. pylori-associated dyspepsia. Such an individualized approach makes it possible to select the most effective means for both adjuvant therapy and monotherapy (if necessary).

Gastric microbiocenosis assessment in the presence or absence of Helicobacter pylori. We performed a comparative analysis of the gastric microbiota from 22 patients, 10 with positive H. pylori-status and 12 with negative H. pylori-status. The gastric microbiota of the patients from these two groups differed significantly (Fig. 3).


Figure 3. Quantitative level of various opportunistic bacteria in gastric biopsy specimens from patients with positive and negative H. pylori-status


The chart demonstrates that bacteria from the genera Proteus, Klebsiella and Enterobacter were found only in samples collected from patients infected with H. pylori. We found no statistically significant correlation between the presence of H. pylori and Fusobacterium spp., Faecalibacterium prausnitzii and Bacteroides fragilis, B. thetaiotaomicron, Bifidobacterium spp.

It should be noted that when lactobacilli and enterococci were detected in the gastric samples at a concentration greater than 3 lgCFU/mL, the probability of detecting H. pylori was lower (Fig. 4).


Figure 4. Prevalence of detected gastric H. pylori in patients with dyspepsia with isolated lactobacilli and enterococci


Consequently, as demonstrated on Fig. 3 and Fig. 4, we observe an increased presence of opportunistic pathogen belonging to the Enterobacteriaceae family combined with concurrent regress in numbers of colonies of enterococci and lactobacilli (non-pathogenic microorganism) in H. pylori-positive patients. We suggest that observed imbalance in gastric microbiota can be attributed as an underlying cause for development of symptoms of dyspepsia and following H. pylori-associated diseases.

Gut microbiome study by qPCR. The study was performed by comparing the following microorgamnisms (the quantitative content of representatives of the intestinal microbiota): the total number of bacteria, Acinetobacter spp., Citrobacter spp., Escherichia coli and enteropathogenic E. coli, Proteus spp., Lactobacillus spp., Bifidobacterium spp., Bacteroides thetaiotaomicron, Bacteroides fragilis group, Clostridium difficile, Clostridium perfringens, Enterococcus spp., Faecalibacterium prausnitzii, Fusobacterium nucleatum and Parvimonas micra.

Changes in the microbiota before and after therapy had no significant differences in patients receiving probiotics and autoprobiotics. When considering the composition of the microbiota before and after therapy of all patients, it was shown that the quantitative content of Ruminococcus, Metanobrevibacterium, Roseburia, Eubacterium, Blautia, Enterococcus increased. The populations of Prevotella, Streptococcus, Salmonella, Parvimonas Fusobacterium, Citrobacter, Klebsiella, Enterobacter, Bacteroides theiotaomicron on the contrary decreased (Fig. 5).


Figure 5. Gut microbiota profile before and after autoprobiotic- and probiotic-therapy of H. pylori+ gastritis


Assessment of the clinical impact in treatment of H. pylori infection. Within the main group of patients, we distinguished a separate cohort of 11 patients who previously had recorded allergic reactions to antibiotics that are used in standard eradication treatment regimens. This cohort was divided into two subgroups: one received probiotic alone (5 patients) and the other received solely autoprobiotic therapy (6 patients). The summarized results for clinical efficacy in relieving the symptoms of dyspepsia and the anti-Helicobacter activity of these drugs is demonstrated in Tables 1 and 2.


Table 1. Evaluation of the clinical effectiveness for autoprobiotics and probiotics in reversing symptoms in patients with Helicobacter pylori-associated dyspepsia

Symptom, frequency in %



Before treatment

After treatment

Before treatment

After treatment











Epigastric pain
















Table 2. Evaluation of the clinical effectiveness of autoprobiotics and probiotics in Helicobacter pylori eradication


Autoprobiotic (n = 10)

Probiotic (n = 12)

Effectiveness of anti-Helicobacter action: number of H. pylori-negative samples based on stool antigen test (immunochromatographic method), % (n)

83 (5)

60 (2)


According to questionnaire assessment symptoms of dyspepsia were completely eliminated after treatment with autoprobiotic and probiotic. The use of autoprobiotics based on indigenous enterococci alone is more effective in eradicating H. pylori than the use of a starter culture based on the E. faecium L3 strain.


The prerequisite for this study were problems with the use of antibiotics, such as insufficient efficacy and side effects (diarrhea, nausea, bloating, allergic reactions etc.). In this study, for the first time, the possibility of using autoprobiotics in monotherapy of H. pylori-associated dyspepsia is considered.

The choice of the type of autoprobiotic was associated with the high efficiency of autoprobiotic enterococci in the correction of gut dysbiosis, therapy of irritable bowel syndrome and metabolic syndrome. In addition, this study has already revealed an inverse correlation between the presence of enterococci in stomach biopsies and enterococcus and lactobacilli.

It is not surprising that when correcting the microbiota of the gastrointestinal tract with the help of indigenous enterococci isolated from the patient’s feces, the elimination of the pathogen and the disappearance of dyspeptic symptoms were observed. Previously, such effects were described with the introduction of several probiotics, among which some of the most effective were based on Enterococcus faecium [21].

In vitro studies have demonstrated a high sensitivity of H. pylori to probiotics based on enterococci, including autoprobiotic, comparable to sensitivity to antibiotics. As it was shown earlier, the effect of probiotics is associated with the production of enterocins [6].

The intake of the functional food product containing E. faecium L3 and the autoprobiotic starter culture containing E. faecium have many positive effects: the disappearance of pain syndrome, heartburn, belching, flatulence, apparently due to the normalization of the composition of the gut microbiota and H. pylori eradication.

The use of autoprobiotics did not reveal significant differences in the composition of the gut microbiota after administration of probiotic E. faecium L3. The advantage of autoprobiotic can be the duration of the effect of autoprobiotics, established earlier [12].


For the investigated H. pylori strains the sensitivity is similar to both antibiotics used in standard eradication protocols and probiotics. The sensitivity of H. pylori to autoprobiotics based on indigenous enterococci is slightly higher than to probiotics. Treatment regimen with an autoprobiotic based on indigenous enterococci alone showed a higher eradication rate compared to a starter culture based on the E. faecium L3 strain. It is reasonable to include both probiotics and autoprobiotics in comprehensive eradication regimens due to dysbiotic changes of gastric microbiota in patients with dyspepsia and persisting H. pylori infection. When standard anti-helicobacter therapy cannot be used, autoprobiotics should be used as the preferred treatment. Enterococci-based drugs are the most promising for further research into the anti-Helicobacter effect of probiotics and autoprobiotics.


About the authors

Elena I. Ermolenko

Institute of Experimental Medicine; North-Western State Medical University named after I.I. Mechnikov


д.м.н., зав. лабораторией биомедицинской микроэкологии отдела молекулярной микробиологии, профессор кафедры медицинской микробиологии

Russian Federation, St. Petersburg; St. Petersburg

Anastasiya S. Molostova

Institute of Experimental Medicine; North-Western District Scientific and Clinical Center named after L.G. Sokolov, Federal Medical and Biological Agency


врач-гастроэнтеролог, младший научный сотрудник

Russian Federation, St. Petersburg; St. Petersburg

Natalia V. Baryshnikova

Institute of Experimental Medicine; Pavlov First Saint Petersburg State Medical University; St. Petersburg State Pediatric Medical University

ORCID iD: 0000-0001-7429-0336

к.м.н., доцент, научный сотрудник лаборатории молекулярной микробиологии, доцент кафедры внутренних болезней стоматологического факультета, младший научный сотрудник лаборатории медико-социальных проблем педиатрии

Russian Federation, St. Petersburg; St. Petersburg; St. Petersburg

Alena V. Svarval

St. Petersburg Pasteur Institute

Author for correspondence.
ORCID iD: 0000-0001-9340-4132

к.м.н., старший научный сотрудник, зав. лабораторией идентификации патогенов

Russian Federation, 14, Mira str., St. Petersburg, 197101

Nikita S. Gladyshev

St. Petersburg Pasteur Institute; St. Petersburg State University

Scopus Author ID: 57221052753
ResearcherId: S-9158-2018

лаборант лаборатории идентификации патогенов, студент образовательной программы «Лечебное дело» медицинского факультета

Russian Federation, 14, Mira str., St. Petersburg, 197101; St. Petersburg

Victor A. Kashchenko

St. Petersburg State University; North-Western District Scientific and Clinical Center named after L.G. Sokolov, Federal Medical and Biological Agency


д.м.н., профессор, зав. кафедрой факультетской хирургии, зам. генерального директора по научно-образовательной работе, главный хирург

Russian Federation, St. Petersburg; St. Petersburg

Alexander N. Suvorov

Institute of Experimental Medicine; St. Petersburg State University

ORCID iD: 0000-0003-2312-5589

член-корреспондент РАН, д.м.н., профессор, зав. отделом молекулярной микробиологии, зав. кафедрой фундаментальных проблем медицины и медицинских технологий факультета стоматологии и медицинских технологий

Russian Federation, St. Petersburg; St. Petersburg


  1. Боровкова Е.А., Алиева Е.В. Микробиологическое исследование микрофлоры толстого кишечника на дисбактериоз в оценке эффективности аутопробиотикотерапии // Естественные и технические науки. 2020. Т. 8, № 146. С. 24–33. [Borovkova E.A., Alieva E.V. Microbiological examination of the microflora of the large intestine for dysbacteriosis in assessing the effectiveness of autoprobiotic therapy. Estestvennye i tekhnicheskie nauki = Natural and Technical Sciences, 2020, vol. 8, no. 146, pp. 24–33. (In Russ.)]
  2. Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А., Трухманов А.С., Баранская Е.К., Абдулхаков Р.А., Алексеева О.П., Алексеенко С.А., Дехнич Н.Н., Козлов Р.С., Кляритская И.Л., Корочанская Н.В., Курилович С.А., Осипенко М.Ф., Симаненков В.И., Ткачев А.В., Хлынов И.Б., Цуканов В.В. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018. Т. 28, № 1. С. 55–70. [Ivashkin V.T., Mayev I.V., Lapina T.L., Sheptulin A.A., Trukhmanov A.S., Baranskaya Y.K., Abdulkhakov R.A., Alekseyeva O.P., Alekseyenko S.A., Dekhnich N.N., Kozlov R.S., Klyaritskaya I.L., Korochanskaya N.V., Kurilovich S.A., Osipenko M.F., Simanenkov V.I., Tkachev A.V., Khlynov I.B., Tsukanov V.V. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2018, vol. 28, no. 1, pp. 55–70. (In Russ.)] doi: 10.22416/1382-4376-2018-28-1-55-70
  3. Лазебник Л.Б., Ткаченко Е.И., Абдулганиева Д.И., Абдулхаков Р.А., Абдулхаков С.Р., Авалуева Е.Б., Ардатская М.Д., Ахмедов В.А., Бордин Д.С., Бурков С.Г., Бутов М.А., Голованова Е.В., Голофеевский В.Ю., Гриневич В.Б., Джулай Г.С., Добрица В.П., Еремина Е.Ю., Жигалова Т.Н., Иваников И.О., Исаков В.А., Казюлин А.Н., Калинин А.В., Козлова И.В., Комиссаренко И.А., Корниенко Е.А., Корочанская Н.В., Курилович С.А., Кучерявый Ю.А., Ли Е.Д., Ли И.А., Левченко С.В., Ливзан М.А., Логинов А.Ф., Лоранская И.Д., Маев И.В., Максимов В.А., Миллер Д.А., Минушкин О.Н., Низов А.А., Орешко Л.С., Осипенко М.Ф., Пальцев А.И., Пасечников В.Д., Радченко В.Г., Рустамов М.Н., Саблин О.А., Сагынбаева В.Э., Сайфутдинов Р.Г., Самсонов А.А., Сарсенбаева А.С., Селиверстов П.В., Симаненков В.И., Ситкин С.И., Старостин Б.Д., Суворов А.Н., Тарасова Л.В., Ткачев А.В., Успенский Ю.П., Хлынова О.В., Хомерики Н.М., Хомерики С.Г., Цуканов В.В., Чернин В.В., Чернышев А.Л., Шархун О.О., Щербаков П.Л., Яковенко Э.П. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московские соглашения) // Экспериментальная и клиническая гастроэнтерология. 2017. № 2. С. 3–21. [Lazebnik L.B., Tkachenko E.I., Abdulganiyeva D.I., Abdulkhakov R.A., Abdulkhakov S.R., Avaluyeva E.B., Ardatskaya M.D., Akhmedov V.A., Bordin D.S., Burkov S.G., Butov M.A., Golovanova E.V., Golofeyevskiy V.Yu., Grinevich V.B., Dzhulay G.S., Dobritsa V.P., Eremina E.Yu., Zhigalova T.N., Ivanikov I.O., Isakov V.A., Kazyulin A.N., Kalinin A.V., Kozlova I.V., Komissarenko I.A., Kornienko E.A., Korochanskaya N.V., Kurilovich S.A., Kucheryavyy Yu.A., Li E.D., Li I.A., Levchenko S.V., Livzan M.A., Loginov A.F., Loranskaya I.D., Mayev I.V., Maksimov V.A., Miller D.A., Minushkin O.N., Nizov A.A., Oreshko L.S., Osipenko M.F., Pal’tsev A.I., Pasechnikov V.D., Radchenko V.G., Rustamov M.N., Sablin O.A., Sagynbayeva V.E., Sayfutdinov R.G., Samsonov A.A., Sarsenbayeva A.S., Seliverstov P.V., Simanenkov V.I., Sitkin S.I., Starostin B.D., Suvorov A.N., Tarasova L.V., Tkachev A.V., Uspenskiy Yu.P., Khlynova O.V., Khomeriki N.M., Khomeriki S.G., Tsukanov V.V., Chernin V.V., Chernyshev A.L., Sharkhun O.O., Scherbakov P.L., Yakovenko E.P. VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter pylori-associated diseases (VI Moscow agreement). Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology, 2017, no. 2, pp. 3–21. (In Russ.)]
  4. Симаненков В.И., Захарова Н.В., Жебрун А.Б., Сварваль А.В., Савилова И.В., Ферман Р.С. Резистентность Helicobacter pylori к антимикробным препаратам по результатам бактериологического тестирования // Лечащий врач. 2015. № 4: 91. [SimanenkovV.I., ZakharovaN.V., ZhebrunA.B., Svarval’ A.V., SavilovaI.V., FermanR.S. Resistance of Helicobacter pylori to antimicrobial preparations by the results of bacteriologic testing. Lechashchii vrach = Lechashchii Vrach, 2015, no. 4: 91. (In Russ.)] URL:
  5. Патент № 2546253 Российская Федерация, МПК C12N 1/20 (2006.01), C12Q 1/68 (2006.01), A61K 35/74 (2015.01), A23C 9/123 (2006.01). Способ получения персонифицированного аутопробиотического продукта и способ лечения синдрома раздраженного кишечника с использованием этого продукта; № 2013120765/10; заявлено 25.04.2013: опубликовано: 10.04.2015 / Симаненков В.И., Суворов А.Н., Соловьева О.И., Ермоленко Е.И., Цапиева А.Н., Сундукова З.Р. Патентообладатель: Симаненков В.И., Суворов А.Н. 23 с. [Patent No. 2546253 Russian Federation, Int. C12N 1/20 (2006.01), C12Q 1/68 (2006.01), A61K 35/74 (2015.01), A23C 9/123 (2006.01). Method of obtaining personified autoprobioticproduct and method of treating syndrome of irritable bowl with thereof application. No. 2013120765/10; application: 25.04.2013: date of publication 10.04.2015 / Simanenkov V.I., Suvorov A.N., Solov’eva O.I., Ermolenko E.I., Tsapieva A.N., Sundukova Z.R. Proprietors: Simanenkov V.I., Suvorov A.N. 23 p.]
  6. Суворов А.Н., Барышникова Н.В., Сварваль А.В., Ниязов Р.М. Возможности некоторых пробиотических штаммов в эрадикации Helicobacter pylori in vitro и in vivo // Фарматека. 2018. № 2. С. 74–78. [Suvorov A.N., Baryshnikova N.V., Svarval A.V., Niyazov R.M. Possibilities of some probiotic strains in the eradication of Helicobacter pylori in vitro and in vivo. Farmateka = Pharmateca, 2018, no. 2, pp. 74–78. (In Russ.)]
  7. Ткаченко Е.И., Успенский Ю.П., Барышникова Н.В. Оптимизация лечения заболеваний, ассоциированных с Helicobacter pylori // Врач. 2012. no. 1, pp. 36–38. [Tkachenko E., Uspenskiy Yu., Baryshnikova N. Optimization of treatment for Helicobacter pylori-associated diseases. Vrach = Physician, 2012, no. 1, pp. 36–38. (In Russ.)]
  8. Цапиева А.Н., Боровкова Е.А., Карасева А.Б., Алиева Е.В., Суворов А.Н. Разработка метода идентификации индигенных лактобацилл кишечника при создании аутопробиотиков // Вопросы детской диетологии. 2019. Т. 17, № 3, pp. 52–59. [Tsapieva A.N., Borovkova E.A., Karaseva A.B., Alieva E.V., Suvorov A.N. Development of a method for identification of indigenous gut lactobacilli in the creation of autoprobiotics. Voprosy detskoi dietologii = Pediatric Nutrition, 2019, vol. 17, no. 3, pp. 52–59. (In Russ.)] doi: 10.20953/1727-5784-2019-3-52-59
  9. Boonyaritichaikij S., Kuwabara K., Nagano J., Kobayashi K., Koga Y. Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection. Helicobacter, 2009, vol. 14, no. 3, pp. 202–207. doi: 10.1111/j.1523-5378.2009.00675.x
  10. Canducci F., Cremonini F., Armuzzi A., Di Caro S., Gabrielli M., Santarelli L., Nista E., Lupascu A., De Martini D., Gasbarrini A. Probiotics and Helicobacter pylori eradication. Dig. Liver. Dis., 2002, vol. 34, suppl. 2, pp. S81–S83. doi: 10.1016/s1590-8658(02)80172-4
  11. Dore M.P., Cuccu M., Pes G.M., Manca A., Graham D.Y. Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern. Emerg. Med., 2014, vol. 9, no. 6, pp. 649–654. doi: 10.1007/s11739-013-1013-z
  12. Ermolenko E.I., Abdurasulova I.N., Kotyleva M.P., Svirido D.A., Matsulevich A.V., Karaseva A.B. Effects of indigenous enterococci on the intestinal microbiota and the behavior of rats. Neurosci. Behav. Physiol., 2018, vol. 48, no. 4, pp. 496–505. doi: 10.1007/s11055-018-0591-7
  13. Gotteland M., Poliak L., Cruchet S., Brunser O. Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori. Acta Paediatr., 2005, vol. 94, no. 12, pp. 1747–1751. doi: 10.1111/j.1651-2227.2005.tb01848.x
  14. Losurdo G., Cubisino R., Barone M., Principi M., Leandro G., Ierardi E., Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: a systematic review with pooled-data analysis. World J Gastroenterol., 2018, vol. 24, no. 1, pp. 139–149. doi: 10.3748/wjg.v24.i1.139
  15. Lü M., Yu S., Deng J., Yan Q., Yang C., Xia G., Zhou X. Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One, 2016, vol. 11, no. 10: e0163743. doi: 10.1371/journal.pone.0163743
  16. Malfertheiner P., Megraud F., O’Morain C.A., Atherton J., Axon A.T., Bazzoli F., Gensini G.F., Gisbert J.P., Graham D.Y., Rokkas T., El-Omar E.M., Kuipers E.J.; European Helicobacter Study Group. Management of Helicobacter pylori infection — the Maastricht IV/Florence Consensus Report. Gut, 2012, vol. 61, no. 5, pp. 646–664. doi: 10.1136/gutjnl-2012-302084
  17. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M.; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut., 2017, vol. 66, no. 1, pp. 6–30. doi: 10.1136/gutjnl-2016-312288
  18. Molina-Infante J., Gisbert J.P. Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. Rev. Esp. Enferm. Dig., 2013, vol. 105, no. 8, pp. 441–444. doi: 10.4321/s1130-01082013000800001
  19. Rosania R., Minenna M.F., Giorgio F., Facciorusso A., De Francesco V., Hassan C., Panella C., Ierardi E. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm. Allergy Drug Targets., 2012, vol. 11, no. 3, pp. 244–249. doi: 10.2174/187152812800392698
  20. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis. Medicine (Baltimore), 2019, vol. 98, no. 15: e15180 doi: 10.1097/MD.0000000000015180
  21. Suvorov A., Karaseva A., Kotyleva M., Kondratenko Y., Lavrenova N., Korobeynikov A., Kozyrev P., Kramskaya T., Leontieva G., Kudryavtsev I., Guo D., Lapidus A., Ermolenko E. Autoprobiotics as an approach for restoration of personalised microbiota. Front. Microbiol., 2018, no. 9: 1869. doi: 10.3389/fmicb.2018.01869
  22. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment. Pharmacol. Ther., 2010, vol. 32, no. 9, pp. 1069–1079. doi: 10.1111/j.1365-2036.2010.04457.x
  23. Wang F., Feng J., Chen P., Liu X., Ma M., Zhou R., Chang Y., Liu J., Li J., Zhao Q. Probiotics in Helicobacter pylori eradication therapy: systematic review and network meta-analysis. Clin. Res. Hepatol. Gastroenterol., 2017, vol. 41, no. 4, pp. 466–475. doi: 10.1016/j.clinre.2017.04.004
  24. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J. Gastroenterol., 2015, vol. 21, no. 14, pp. 4345–4357. doi: 10.3748/wjg.v21.i14.4345

Supplementary files

Supplementary Files
1. Figure 1. Prevalence of detected of H. pylori strains sensitive to antibacterial drugs

Download (73KB)
2. Figure 2. Prevalence of detected H. pylori strains sensitive to probiotics and autoprobiotics

Download (71KB)
3. Figure 3. Quantitative level of various opportunistic bacteria in gastric biopsy specimens from patients with positive and negative H. pylori-status

Download (72KB)
4. Figure 4. Prevalence of detected gastric H. pylori in patients with dyspepsia with isolated lactobacilli and enterococci

Download (61KB)
5. Figure 5. Gut microbiota profile before and after autoprobiotic- and probiotic-therapy of H. pylori+ gastritis

Download (89KB)

Copyright (c) 2022 Ermolenko E.I., Molostova A.S., Baryshnikova N.V., Svarval A.V., Gladyshev N.S., Kashchenko V.A., Suvorov A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies